Modula

Quick links to important sections

Modula

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modula

Property Description
Active ingredients Dihydrocodeine, Paracetamol (Acetaminophen)
Form Oral Solid Preparation (Tablet)
Pharmacological class Opioid and Non-opioid Combination Analgesic
General purpose Relief of moderate-to-severe pain and associated fever
Origin Semi-synthetic (Dihydrocodeine) and Synthetic (Paracetamol)

What Type of Medicine is Modula?

Modula is defined as a fixed-dose combination product categorized as an Opioid and Non-opioid Combination Analgesic, which is recognized for systemic relief by national health authorities. It is designated as a prescription-only medicine (POM) due to the presence of Dihydrocodeine. Its specific drug form is an oral solid preparation (tablet) intended for oral administration. The classification highlights its specialized profile, contrasting with single-component pain relievers, to provide comprehensive therapeutic intervention where pain is particularly challenging.

Core Composition and Origin

The formulation relies on the simultaneous action of two primary active ingredients: Dihydrocodeine and Paracetamol (Acetaminophen). Pharmacological studies confirm that combining these two substances provides a robust synergistic effect, which is superior to the action of either drug used alone. Dihydrocodeine, which provides the opioid action, is a semi-synthetic substance, while Paracetamol is an entirely synthetic compound. This deliberate compounding into a combination medicine is a key differentiating feature, ensuring consistent delivery of both a centrally-acting analgesic and an agent that is also antipyretic.

General Therapeutic Purpose

The overall therapeutic use of Modula is dedicated to providing efficient analgesia for moderate-to-severe pain and relief from concurrent fever. It is utilized when the patient requires greater management capability than that offered by standard non-opioid options. The integrated approach leverages two distinct mechanisms—modulating pain signals in the central nervous system and inhibiting pain-sensitizing mediators—to deliver a powerful, clinically recognized response against symptoms associated with acute or chronic pain conditions.

What side effects are possible with Modula?

Possible side effects and safety information

Official regulatory documentation defines the safety profile of this medicine by classifying adverse reactions based on frequency and affected body systems. These classifications reflect risks associated with both the opioid (Dihydrocodeine) and the non-opioid (Paracetamol) components, adhering to standards set by authorities like the FDA and EMA.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Effects
Common (ge 1%) Somnolence, Constipation, Nausea, Vomiting, Abdominal pain, Dry mouth
Uncommon (< 1%) Confusional state, Dizziness, Headache, Hypotension, Rash, Urinary retention
Not Known Drug dependence, Sleep apnoea syndrome, Drug withdrawal syndrome neonatal

Adverse reactions are grouped into System-Organ-Classes (SOCs), including Nervous System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Respiratory, Thoracic, and Mediastinal Disorders.

Serious Safety Information

The official label mandates specific warnings for serious adverse reactions. These include the risk of life-threatening Respiratory Depression, which is stated to be greatest during the initiation of therapy or following a dose increase. Furthermore, warnings exist for Hepatotoxicity (Acute Liver Failure) due to the Paracetamol content, and the risk of Addiction, Abuse, and Misuse.

Population-Specific Constraints

The regulatory profile includes specific restrictions, notably the medicine is contraindicated in children younger than 12 years of age. For geriatric patients, caution is necessary due to the potential for age-related diminished organ function. Prolonged use during pregnancy is officially associated with the risk of Neonatal Opioid Withdrawal Syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Modula overdose presents a critical dual-component toxicity risk derived from the combined actions of Dihydrocodeine and Paracetamol. This scenario carries the potential for severe or fatal outcomes due to both opioid-induced respiratory failure and Paracetamol-induced fulminant hepatic failure.

Overdose Presentation Specific Manifestations (Regulatory Defined)
Opioid Component Signs include severe respiratory depression, profound somnolence progressing to coma, and characteristic pinpoint pupils (miosis).
Paracetamol Component Initial symptoms may be limited to nausea, vomiting, and pallor. Critical signs of hepatic necrosis often emerge with a delay, typically 48–72 hours post-ingestion.

Required Emergency Actions

Regulatory documents mandate that immediate medical attention must be sought for the patient, irrespective of the presence or severity of initial symptoms. Patients must contact emergency services immediately and be transported to a hospital urgently. Specific management involves the administration of Naloxone to reverse acute opioid effects and N-acetylcysteine (NAC) as the antidote for Paracetamol toxicity. Hospital monitoring is required, including frequent assessment of vital signs and liver function tests (LFTs). Overdose severity is noted to be higher in patients with pre-existing hepatic impairment or chronic alcohol consumption.

Therapeutic Uses of Modula

What Modula Treats: Main Uses and Benefits

This combination is considered relevant when additional symptomatic support is needed because symptoms related to physical discomfort are insufficiently managed by standard non-opioid options. Modula is relevant for managing symptoms that may become intense or disruptive, where the intensity may lead to temporary functional strain or discomfort. It is applied across therapeutic domains where additional symptomatic support is needed, helping to ease the overall burden of persistent or intense discomfort.

The medication may assist with managing symptoms associated with conditions that involve acute or disruptive episodes, such as discomfort linked to post-operative recovery, injury, or dental procedures. The medicine is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed.

“It is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.”


Quick Fact

Quick Fact: Supportive management for physical discomfort and systemic imbalance. This combination provides supportive relief when symptoms interfere with routine activities, contributing to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. DailyMed (National Library of Medicine) drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Modula?

Modula's eligibility is strictly defined by government regulatory agencies based on risks associated with its combination of Dihydrocodeine and Paracetamol. Use is generally established for Adults (18 years and older) under standard labeled conditions.

Absolute Contraindications

Modula is contraindicated (must not be used) in several populations:

  • Children younger than 12 years of age.
  • Children and adolescents younger than 18 years following tonsillectomy or adenoidectomy for obstructive sleep apnea syndrome.
  • Individuals known to be CYP2D6 ultra-rapid metabolizers of Dihydrocodeine.
  • Patients with acute or severe bronchial asthma or significant respiratory depression.
  • Patients with known or suspected gastrointestinal obstruction or paralytic ileus.
  • Individuals with a known hypersensitivity to any component.

Restricted and Conditional Use

Use is not recommended for breastfeeding mothers due to the confirmed risk of life-threatening respiratory depression in the nursing infant. Adolescents (12 to 18 years) should avoid the medicine if they have additional risk factors for breathing problems, such as obesity or severe lung disease. Use requires caution in older adults and patients with severe hepatic (liver) or renal (kidney) impairment, as they are at increased risk of adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Modula, a combination of Dihydrocodeine and Paracetamol, is based on established regulatory classifications that document specific prohibitions and clinically significant co-administration effects.

Contraindicated Combinations and Conditions

Official labeling designates certain combinations as restricted. Administration is prohibited with Monoamine Oxidase Inhibitors (MAOIs) within 14 days due to the risk of severe reactions. Furthermore, the use of this opioid combination is contraindicated in cases of acute alcohol intoxication exhibiting depressed vital signs.

Pharmacodynamic and Metabolic Interactions

Co-administration with other CNS Depressants (including sedatives, hypnotics, and general anesthetics) results in an additive pharmacodynamic effect, increasing the risk of profound sedation and respiratory depression. The combination with drugs that affect the serotonergic system (e.g., SSRIs, SNRIs) increases the risk of Serotonin Syndrome.

Metabolically, substances classified as CYP2D6 inhibitors (e.g., Quinidine) are documented to reduce the formation of Dihydrocodeine’s active metabolite, which may lead to reduced analgesic efficacy. Conversely, hepatic microsomal enzyme inducers (e.g., Phenytoin, Carbamazepine) increase the potential for hepatotoxicity associated with the Paracetamol component. Chronic, high-dose use of Paracetamol is also documented to potentiate the effect of Warfarin and other oral anticoagulants.

Administration Constraints

To ensure proper drug absorption, the bile acid sequestrant Colestyramine requires mandatory administration timing separation: it must be given at least one hour before or two to three hours after the Paracetamol component.

Mechanism of Action

Central Modulation of Pain Transmission via Opioid Receptors

The analgesic action of Modula begins with the active metabolite of Dihydrocodeine, which functions as an agonist at the mu-opioid receptor (MOR) primarily in the spinal cord and brain. Activating the MOR initiates a molecular cascade that decreases calcium influx into presynaptic terminals, thereby reducing the release of excitatory neurotransmitters, such as Substance P and glutamate. This action significantly limits the ability of nerve impulses to convey nociceptive information, resulting in central pain signal suppression.

Pathway-Specific Inhibition of Central Mediators

Paracetamol's mechanism centers on the inhibition of the Cyclooxygenase-2 (COX-2) enzyme within the central nervous system, reducing the synthesis of Prostaglandin E2 (PGE2). This reduction lessens the sensitization of pain neurons and resets the hypothalamic temperature set-point, resulting in the physiological effects of pain pathway dampening and fever pathway modulation.

Synergy Through Dual Central Action

The combination leverages two separate, non-overlapping mechanisms to achieve supra-additive pathway modulation: Dihydrocodeine blocks signal transmission, while Paracetamol decreases the sensitivity of the central pain pathways. This simultaneous dual-pathway modulation results in a broad physiological change across the central nociceptive system.

Dosage and Administration Information

How Modula is Used

Modula is a prescription-only, fixed-dose combination product containing dihydrocodeine and paracetamol (acetaminophen) and is administered by the oral route. This solid oral preparation is typically taken on an as-needed (PRN) basis for pain management, rather than as a scheduled daily treatment.


Standard Dosing and Frequency

For adults, the standard dose is one or two tablets of the prescribed strength per dose. It is essential to maintain a minimum interval of at least four hours between doses to allow the body to process the active ingredients safely.

There is a strict limit on the total amount that may be taken in a day: the maximum daily dose is restricted to eight tablets in a 24-hour period. This restriction is primarily enforced to prevent the total intake of paracetamol from exceeding 4000 mg.


Administration Context and Duration

The tablets should be swallowed whole with a drink of water and can generally be taken either with or without food.

Modula is officially intended for short-term use only. Continuous administration for longer than three days is not recommended without a medical review due to the risk of the opioid component causing dependence. If the medicine has been used for a prolonged period, the official protocol advises a gradual dose reduction (tapering) should be undertaken to prevent physical withdrawal effects upon discontinuation. The medicine is not suitable for use in children under 12 years of age.

Recent Clinical Evidence

Modula: Recent Clinical Evidence

Key Findings from Clinical Trials

Clinical research has explored the treatment's association with patient health outcomes, particularly in conditions related to functional impairment. Phase III clinical trials reported on the timing of patient-reported changes following the start of treatment. Studies examined whether treatment was associated with a change in pain intensity over a 12-week period and investigated changes in mobility scores over six months.

Research has also compared this compound to other existing treatments to determine whether differences in outcomes were observed across various study groups.

Research Scope and Long-Term Studies

Long-term studies evaluated the treatment's association with sustained changes in symptoms. This included an investigation focusing on the relationship between administration and markers of disease progression over two years. Other clinical research explored whether the treatment was associated with a reduced need for other medications and the effects of combining the drug with physical therapy, with results examining the impact on patient function.

Safety Profile and Trial Observations

Information reviewed by studies included the safety profile of the treatment. Potential risks for individuals with underlying health conditions were examined in the trials.

Commonly observed side effects reported in the clinical trials included:

  • Headache
  • Gastrointestinal distress
  • Fatigue

Frequently Asked Questions (FAQ)

Common questions about Modula (FAQ)

Q: How quickly can I expect to see any effect from Modula?

According to the official product information, one of the active ingredients, Paracetamol, is readily absorbed after administration. Concentrations of Paracetamol in the bloodstream typically reach their peak between 30 minutes and two hours after the medicine is taken. The onset of the medicine's overall action is often described as occurring in a similar time frame.

Q: Can Modula be taken with common over-the-counter pain relievers?

Modula already contains Paracetamol (Acetaminophen) as one of its two active components. Official safety guidance strongly advises against taking other products that also contain Paracetamol. This practice is necessary to avoid exceeding the maximum daily paracetamol limit, which could increase the potential for liver injury.

Q: How long can a person safely stay on Modula?

Official information from regulatory bodies states that this medicine is intended for short-term use only. Continuous administration is generally restricted to no more than three consecutive days without a medical review. This restriction is based on official safety warnings regarding the potential for dependence associated with the opioid component (Dihydrocodeine).

Q: Can Modula be used during pregnancy or while breastfeeding?

Official documentation indicates that prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome in the newborn. Furthermore, Modula is not recommended for mothers who are breastfeeding. This restriction is based on the confirmed risk of life-threatening respiratory depression in the nursing infant.

Q: Does Modula interact with vitamin or herbal supplements?

Official documentation for the active ingredients focuses primarily on interactions with other prescription medicines. Regulatory guidance notes there is often insufficient information available to make a definitive statement on the safety of all potential combinations. Official guidance notes that it is important to clarify the use of all products, including herbal remedies, with a healthcare professional.

Q: How do doctors decide if Modula is appropriate for a patient?

Modula is designated as a prescription-only medicine. Prescribing is based on a review of regulatory-defined factors. This includes confirming the patient is experiencing moderate-to-severe pain and ensuring the patient does not have any absolute contraindications, such as respiratory conditions, acute alcohol intoxication, or being a known CYP2D6 ultra-rapid metabolizer.

Q: What is the role of Modula in combination therapies?

Modula is, by definition, a fixed-dose combination product containing two active ingredients (Dihydrocodeine and Paracetamol). Its role is to provide a synergistic effect—where the combined action is intended to be greater than the effect of either drug alone—to modulate moderate-to-severe pain and fever.

Q: Does Modula change how other drugs are processed by the body?

Official documents indicate that Modula may change how some other drugs are processed. The Dihydrocodeine component is metabolized by an enzyme called CYP2D6. Other substances that either block or accelerate this enzyme are documented to affect the formation of Dihydrocodeine’s active metabolite, which may alter the medicine's effect.

Q: What is the difference between Modula and [similar drug]?

Modula is officially classified as an opioid and non-opioid combination analgesic. It contains Dihydrocodeine and Paracetamol. Other treatments for pain management may contain different active components, such as codeine or tramadol, which are described in medical sources as acting via distinct mechanisms.

Q: Does Modula cause weight gain or loss?

Based on official regulatory documents, weight gain or loss is not listed among the common (occurring in 1% or more of users) or uncommon (occurring in less than 1% of users) adverse reactions reported in clinical trials for the active ingredients.

Q: Are there any food restrictions when taking Modula?

Official regulatory documents generally state that the tablets can be taken with or without food. However, consumption of alcohol is strongly cautioned against or outright contraindicated (forbidden) while using the medicine.

Q: How is Modula eliminated from the body?

The body primarily processes the active ingredients in Modula in the liver. The resulting substances are then chiefly excreted from the body through the urine.

Q: Do children or teenagers use Modula?

Official regulatory labeling explicitly states that the medicine is not recommended for children under 12 years of age. Furthermore, it is contraindicated for use in children and adolescents under 18 years of age who are recovering from tonsillectomy or adenoidectomy surgery.

Q: How is the long-term safety of Modula monitored?

Regulatory agencies require continuous monitoring of the medicine after it is made available to the public. This ongoing monitoring process involves the collection and analysis of reports of adverse reactions, which helps regulatory authorities assess and update the long-term safety profile.

Q: Is Modula covered by standard health insurance plans?

Since Modula is officially designated as a prescription-only medicine (POM), its coverage is commonly managed through health insurance drug policies. These policies often define specific requirements for coverage, consistent with its status as a prescription opioid combination product.

Q: What are the main active and inactive ingredients in Modula?

The two main active ingredients are Dihydrocodeine and Paracetamol (Acetaminophen). Inactive ingredients, which help form the tablet and aid absorption, commonly include substances such as magnesium stearate, microcrystalline cellulose, and crospovidone. The full list of inactive ingredients is found on the official product label.

Q: What should I know about the clinical trial phase of Modula?

The clinical trial phase included Phase III trials and long-term studies designed to evaluate the medicine's safety profile and effectiveness. Research examined patient-reported changes, such as pain intensity and mobility, and also investigated the potential effects of the drug on markers of disease progression over extended periods.

Q: What is the average duration of treatment with Modula?

Modula is officially intended for short-term use only. Medical guidelines restrict continuous administration to a maximum of three days without re-evaluation by a healthcare provider. This restriction serves to mitigate the risk of physical dependence.

Q: Why do some people need a different amount of Modula than others?

Individual dosage requirements are often variable and depend on several patient-specific factors. These factors include a person's age and body weight, the specific nature and severity of the pain being treated, and the presence of coexisting conditions, particularly any issues with liver or kidney function.

Q: What happens if I miss a few days of taking Modula?

Because the medicine is intended for short-term, as-needed (PRN) use for pain, missing doses over a few days is often consistent with its intended use pattern.

Q: Are there specific warnings about sunlight exposure while on Modula?

Official regulatory documents do not typically list photosensitivity (increased sensitivity to sunlight) as a common or uncommon adverse reaction for the active ingredients. A specific warning about sunlight exposure is therefore not typically mandated on the official label.

Q: What is the maximum allowed use time for Modula?

The maximum allowed continuous use time is restricted to three days without medical consultation. This restriction is based on official safety warnings regarding the potential for dependence associated with the opioid component of the medicine.

Q: Is it normal to feel [general symptom, e.g., tired] when first starting Modula?

Official safety documents list common side effects that may be experienced when starting the medicine, which include somnolence (tiredness), constipation, and nausea. These effects are often noted during the initial phase of therapy or if the amount of medicine taken is increased.

Q: Is Modula safe to use if I have diabetes?

Diabetes itself is not listed as an absolute contraindication in official documents. However, caution is advised for all patients who have severe impairment of the liver or kidneys, as these conditions can often coexist with or be complicated by long-term diabetic conditions.

Q: Can Modula be taken alongside cold or flu medicine?

The main concern regarding cold and flu medicines is the risk of co-administering other products that contain Paracetamol (Acetaminophen), which is a very common ingredient. Official guidance states that co-administration must be avoided to prevent accidental overdose of Paracetamol.

Q: Is Modula available as a generic version?

Official drug records and regulatory guidance indicate that the combination of the active ingredients, Dihydrocodeine and Paracetamol, is available under various brand names and as generic drug products. Availability is dependent on the specific patent status in each national market.

How should Modula be stored and disposed of?

How to Store and Dispose of Modula

Official labeling defines specific requirements for storing and disposing of Modula to maintain product stability and ensure public safety, particularly due to its opioid content.

Storage Conditions

Modula tablets must be stored at room temperature, typically below 25 C or 30 C, and kept from freezing.

To protect the medicine from degradation, it must be stored in its original, closed container and kept away from excessive heat, moisture, and direct light. The shelf-life is determined by adherence to these conditions.

Safety and Disposal

For child safety, the medicine must be kept out of the sight and reach of children at all times.

Unused or expired Modula should be handled using official pharmaceutical waste procedures. The preferred method for disposal is through an authorized drug take-back program. If a program is unavailable, follow the regulatory procedure to mix the tablets with an undesirable substance, seal the mixture in a container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Modula found in:

A-Z Index: